Literature DB >> 6975158

Predictive ability of Lukes-Collins classification for immunologic phenotypes of childhood non-Hodgkin lymphoma: an institutional series and literature review.

W M Crist, D R Kelly, A H Ragab, M Roper, J C Dearth, R P Castleberry, A Flint.   

Abstract

Tissues from 22 children with non-Hodgkin lymphoma (NHL) were studied pathologically and immunologically. Most children were noted to have marked (B- or T-cell) neoplasms and the Lukes-Collins classification was predictive of immunologic phenotype in cases where markers were present. Our series and a review of the literature demonstrates that most abdominal NHL are B-cell in origin and are often small noncleaved follicular center cell lymphoma (Burkitt type). Most mediastinal primary lesions are T-cell in origin and of convoluted cell morphology. A few neoplasms (often peripheral nodal) lack the characteristic surface immunoglobulin or erythrocyte rosetting properties of B- or T-cell lesions, respectively. Frequently marrow and central nervous system involvement are observed in T-cell lymphomas and are not in frequent in B cell neoplasms. Shared immunologic and clinical features between the B- or T-cell lymphomas and their leukemic counterparts support the concept that they often differ only in the stage of disease progression.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975158     DOI: 10.1002/1097-0142(19811101)48:9<2070::aid-cncr2820480925>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Primary gastrointestinal lymphoma in childhood (up to 18 years of age). A morphological, immunohistochemical and clinical study.

Authors:  H Takahashi; M L Hansmann
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Middle Eastern intestinal lymphoma: a morphological and immunohistochemical study.

Authors:  P Isaacson; H S Al-Dewachi; D Y Mason
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.